Clik here to view.
Harbour BioMed Announces Global Strategic Partnership with Kelun-Biotech to...
SHANGHAI & CHENGDU, China & BOSTON & CRANBURY, N.J. Harbour BioMed today announced it has entered into an exclusive strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical...
View ArticleClik here to view.
Clik here to view.
Therabiopharma (Japan Based Bio-Venture) Reports 10,000 Times Higher Curcumin...
KAWASAKI, Japan Therabiopharma, a Japan based bio-venture, reports that CMG(Curcumin Monoglucuronide) has proven: This press release features multimedia. View the full release here:...
View ArticleClik here to view.
Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials...
NEW YORK & TOKYO Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced amendments to the protocols for two...
View ArticleClik here to view.
和铂医药完成B轮融资8500万美元 加速创新产品线研发
中国上海、荷兰鹿特丹、美国马萨诸塞州剑桥 和铂医药今天宣布成功完成B轮融资8500万美元，以加速公司创新产品线的成长，尤其是公司临床阶段项目及临床前项目的快速推进。本轮融资由新加坡政府投资公司GIC领投，国寿大健康基金、祥峰投资参与，A轮投资机构尚珹资本与君联资本跟投。...
View ArticleClik here to view.
Harbour BioMed Raises $85 Million in Series B Financing to Accelerate Its...
SHANGHAI & ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. Harbour BioMed announced today that it has completed a Series B round financing of $85 million to accelerate the growth of its...
View ArticleClik here to view.
Shionogi Announces U.S. Availability of Mulpleta® (Lusutrombopag) for the...
OSAKA, Japan & FLORHAM PARK, N.J. Shionogi & Co., Ltd. (hereafter “Shionogi”) announced today that Mulpleta® (lusutrombopag), a once-daily, orally administered, small molecule thrombopoietin...
View ArticleClik here to view.
NanOlogy™发布吸入NanoPac治疗肺癌的阳性临床前数据
德克萨斯州沃思堡和达拉斯 (美国商业资讯) — 临床阶段药品开发公司NanOlogy LLC呈报了吸入NanoPac™（亚微米颗粒紫杉醇）的临床前研究数据，非小细胞肺癌(NSCLC)原位动物模型显示，药物在肺组织中的驻留时间延长，肿瘤消退显著，未观察到药物相关的不良反应。在6月召开的ASCO 2018年会期间，该数据以摘要形式呈报，题为“NanoPac吸入治疗裸鼠原位肺癌模型的NSCLC”。...
View ArticleClik here to view.
SanBio: Acquisition of a Patent Portfolio Regarding Cell Medicines Derived...
TOKYO The SanBio Group, a scientific leader in regenerative medicine for neurological disorders, today announced the acquisition of a patent portfolio regarding cell medicines derived from...
View ArticleClik here to view.
NovellusDx and Primetech Sign an Exclusive Dealer Agreement in Japan
TOKYO & JERUSALEM NovellusDx, Ltd. (CEO: Haim Gil-Ad, headquarters: Jerusalem Bio-Park, Hadassah medical center, Ein-Kerem Campus, Israel) and Primetech Co., Ltd. (President: Ryosuke Ogihara,...
View ArticleClik here to view.
Shionogi Announces Upcoming Presentations from Symproic® (naldemedine)...
OSAKA, Japan & FLORHAM PARK, N.J. Shionogi & Co., Ltd. (hereafter “Shionogi”) will present four scientific posters featuring pre-clinical and clinical findings of Symproic® (naldemedine)...
View ArticleClik here to view.
Minomic在美国和中国获得关键专利
悉尼 (美国商业资讯) — Minomic International Ltd (Minomic)是一家专攻实体瘤诊断及治疗商业化及开发的免疫肿瘤学公司，这些实体瘤包括前列腺癌、膀胱癌和胰腺癌。该公司宣布，其“诊断用细胞表面前列腺癌抗原”已获得美国和中国这两个全球关键市场的专利核准。...
View ArticleClik here to view.
BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration...
CAMBRIDGE, Mass. & BEIJING & NEW YORK BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
View ArticleClik here to view.
NUVISAN GROUP继续其增长，新增来自NESTLÉ SKIN HEALTH的部分GALDERMA研发业务
德国新乌尔姆 (美国商业资讯) — NUVISAN GROUP是欧洲领先的合同研究组织(CRO)之一，专注于面向生命科学行业的早期药物开发。8月31日，该公司与NESTLÉ SKIN HEALTH/ GALDERMA签署协议，接管位于法国索菲亚-安蒂波利斯的部分研发业务。...
View ArticleClik here to view.
ニュヴィサン・グループ、ネスレ スキンヘルスからガルデルマの研究開発能力の一部を追加して成長を持続
独ノイウルム （ビジネスワイヤ） — ライフサイエンス業界の初期医薬品開発に傾注する欧州有数のCROであるニュヴィサン・グループは8月31日、ネスレ スキンヘルス／ガルデルマと、フランスのソフィアアンティポリスにある研究開発施設の一部を引き継ぐための契約を締結しました。...
View ArticleClik here to view.
Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase...
SOUTH SAN FRANCISCO, Calif. Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that the...
View ArticleClik here to view.
BIOCAD与SPH协议在中国设立药物制造厂
俄罗斯圣彼得堡 (美国商业资讯) — 在海参崴召开的本年度远东经济论坛上，BIOCAD与上海医药集团股份有限公司(Shanghai Pharmaceuticals Holding)签署谅解备忘录，在中华人民共和国设立两家合资企业，从事若干种高成本单克隆抗体药品的生产、临床开发、注册和市场营销。...
View ArticleClik here to view.
EpimAb Biotherapeutics Announces IND Filing for EMB01 in China and the US
SHANGHAI EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, announced today that it has filed an IND for its most advanced...
View ArticleClik here to view.
2018 Taiwan healthcare+ Expo: 亚洲医疗科技创新论坛-Med x Tech Summit Asia
台北, 台湾 国际级医疗水准与资通讯产业实力，台湾有机会引领医疗科技发展方向，全球首个以「医疗x科技」为主题台湾医疗科技展Taiwan Healthcare+ Expo，即将在11/29～12/02在南港展览馆登场！展会同时举办2018亚洲医疗科技创新论坛Med x Tech Summit...
View ArticleClik here to view.
MEDTEX: Foresee the Next Wave of Healthcare Revolution
TAIPEI, Taiwan Taiwan, with high quality medical service and world’s top IT industry, has becoming one of the leaders in global healthcare technology and provider. On November 29 – 30, MEDTEX will...
View Article